BioLargo (BLGO) Q3 2025 earnings summary

Executive summary

• Portfolio approach with transformative assets in energy tech, medical, odor control, and PFAS solutions, targeting sustainability, human health, and risk diversification.

• Revenue for the nine months ended September 30, 2025, was $7.1M, down 49% year-over-year, primarily due to a sharp decline in sales to Pooph Inc. and related litigation and credit loss expense.

• Net loss for the nine months was $11.0M, compared to $2.6M in the prior year, driven by a $3.85M credit loss from Pooph and lower sales.

• Management expresses substantial doubt about the ability to continue as a going concern without additional capital or increased revenues.

• Ongoing litigation with Pooph Inc. over unpaid royalties, IP rights, and breach of contract, with a countersuit filed.

Financial highlights

• Q3 2025 revenue was $1.21M, down from $4.35M in Q3 2024; nine-month revenue fell 50% year-over-year from $14M to $7M.

• Net loss for Q3 2025 was $7.14M, compared to $0.54M in Q3 2024, including a $3.85M impairment charge related to Pooph.

• Gross profit for the nine months was $3.3M, down from $6.1M in the prior year.

• Cash position at quarter end was $4.5M; total assets over $9M and stockholders' equity above $3M.

• SG&A expenses increased to $8.3M for the nine months, with substantial non-cash expenses from stock options and grants.

Outlook and guidance

• Clyra Medical preparing for late 2025 or early 2026 commercialization, targeting a $732M wound care market.

• Battery tech (Cellinity) positioned for grid-scale energy storage, with MOUs signed in multiple regions and a future valuation target exceeding $2.5B.

• PFAS solution positioned for significant market share as regulatory and customer adoption increases.

• Management expects annual revenues for 2025 to decrease compared to 2024 due to the loss of the Pooph business.

• Gross profits are not expected to be sufficient to fund operations for the remainder of 2025; further investment capital will be needed.